Aimmune Therapeutics Inc (AIMT1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen George Dilly
Employees:
215
8000 MARINA BOULEVARD, SUITE 300, BRISBANE, CA 94005-1884
(650) 614-5220

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy (CODIT) system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Data derived from most recent annual or quarterly report
Market Cap 2.257 Billion Shares Outstanding65.45 Million Avg 30-day Volume 1.626 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.4
Price to Revenue0.0 Debt to Equity0.7309 EBITDA-277.108 Million
Price to Book Value6.0808 Operating Margin0.0 Enterprise Value907.054 Million
Current Ratio7.526 EPS Growth-0.207 Quick Ratio7.302
1 Yr BETA 0.9963 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-24.635 Altman Z-Score-1.4577 Free Cash Flow to Firm -197.999 Million
View SEC Filings from AIMT1 instead.

View recent insider trading info

Funds Holding AIMT1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AIMT1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BEHAR GREGORY

  • Director
No longer subject to file 2020-10-13 0

SOCIETE DES PRODUITS NESTLE S.A.

  • 10% Owner
67,370,034 2020-10-13 0

BJERKHOLT ERIC CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2020-10-10 0

FALBERG KATHRYN E

  • Director
No longer subject to file 2020-10-10 0

ADELMAN DANIEL C MD CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2020-10-10 0

MCDADE MARK

  • Director
No longer subject to file 2020-10-10 0

ENRIGHT PATRICK G

  • Director
No longer subject to file 2020-10-10 0

IWICKI MARK T

  • Director
No longer subject to file 2020-10-10 0

SHEEHY DOUGLAS T. SEE REMARKS

  • Officer
No longer subject to file 2020-10-10 0

HAUMANN BRETT K

  • Director
No longer subject to file 2020-10-10 0

SELTZER STACEY DENENBERG

  • Director
No longer subject to file 2020-10-10 0

DALLAS JAYSON DONALD ALEXANDER PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2020-10-10 0

OXTOBY ANDREW CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2020-10-10 0

SOCIETE DES PRODUITS NESTLE S.A.

NESTLE SA

  • 10% Owner
525,634 2020-02-07 0

ROZENMAN MARY M. SEE REMARKS

  • Officer
13,878 2019-12-31 0

NESTLE HEALTH SCIENCE US HOLDINGS, INC.

SOCIETE DES PRODUITS NESTLE S.A.

NESTLE SA

NIMCO US, INC.

NESTLE US HOLDCO, INC.

  • 10% Owner
11,727,113 2018-12-31 0

BARROWCLIFFE SUSAN E. GENERAL MANAGER, EUROPE

  • Officer
9,375 2018-11-19 0

DILLY STEPHEN GEORGE PRESIDENT AND CEO

  • Officer
  • Director
447,008 2018-06-11 0

KNAPP JEFFREY H CHIEF OPERATING OFFICER

  • Officer
12,151 2018-03-04 0

NESTLE HEALTH SCIENCE US HOLDINGS, INC.

NESTLE SA

NIMCO US, INC.

  • 10% Owner
11,727,113 2018-02-26 0

TAMMENOMS BAKKER JULIET

  • 10% Owner
6,029,785 2018-02-22 0

DESOUZA WARREN L. CHIEF FINANCIAL OFFICER

  • Officer
20,681 2017-04-03 0

LONGITUDE CAPITAL PARTNERS II, LLC

TAMMENOMS BAKKER JULIET

LONGITUDE VENTURE PARTNERS II, L.P.

  • 10% Owner
6,020,410 2016-11-29 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL FUND III, L.P.

TANANBAUM JAMES B.

  • 10% Owner
4,902,920 2016-08-18 0

LONGITUDE CAPITAL PARTNERS II, LLC

LONGITUDE VENTURE PARTNERS II, L.P.

TAMMENOMS BAKKER JULIET

ENRIGHT PATRICK G

  • 10% Owner
7,513,134 2016-03-29 0

ELFONT ROBERT MYLES CHIEF MEDICAL OFFICER

  • Officer
299,002 2016-02-26 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

TANANBAUM JAMES B.

  • 10% Owner
0 2015-08-05 0

RAFF HOWARD V. CHIEF OPERATING OFFICER

  • Officer
428,575 2015-08-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund AIMT1 -112.0 shares, $-1615.04 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund AIMT1 -228.0 shares, $-3287.76 2020-03-31 N-PORT

Elevate your investments